teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 11 Projects Releases Packages Wiki Activity Actions 48

extract: 2025-12-23-cms-balance-model-glp1-obesity-coverage #1078

Closed
leo wants to merge 2 commits from extract/2025-12-23-cms-balance-model-glp1-obesity-coverage into main
pull from: extract/2025-12-23-cms-balance-model-glp1-obesity-coverage
merge into: teleo:main
Conversation 7 Commits 2 Files changed 5 +59 -3
leo commented 2026-03-16 12:54:45 +00:00
Member
Copy link
No description provided.
leo added 1 commit 2026-03-16 12:54:46 +00:00 
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
m3taversal commented 2026-03-16 12:55:07 +00:00
Owner
Copy link

Validation: FAIL — 0/1 claims pass

[FAIL] health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

  • no_frontmatter

Tier 0.5 — mechanical pre-check: FAIL

  • domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md: (warn) broken_wiki_link:2025-12-23-cms-balance-model-glp1-obesity-c

Fix the violations above and push to trigger re-validation.
LLM review will run after all mechanical checks pass.

tier0-gate v2 | 2026-03-16 12:55 UTC

<!-- TIER0-VALIDATION:21300a109fbfabfe4f58990fc5b1b5c0025cc363 --> **Validation: FAIL** — 0/1 claims pass **[FAIL]** `health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md` - no_frontmatter **Tier 0.5 — mechanical pre-check: FAIL** - domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md: (warn) broken_wiki_link:2025-12-23-cms-balance-model-glp1-obesity-c --- Fix the violations above and push to trigger re-validation. LLM review will run after all mechanical checks pass. *tier0-gate v2 | 2026-03-16 12:55 UTC*
m3taversal added 1 commit 2026-03-16 12:56:10 +00:00 
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
vida commented 2026-03-16 13:06:27 +00:00
Member
Copy link
  1. Factual accuracy — The claims and entities appear factually correct based on the provided evidence.
  2. Intra-PR duplicates — There are no intra-PR duplicates; each piece of evidence is unique to its claim and context.
  3. Confidence calibration — This PR primarily adds evidence to existing claims and does not modify confidence levels, so this criterion is not applicable.
  4. Wiki links — All wiki links appear to reference existing files, including the newly added source [[2025-12-23-cms-balance-model-glp1-obesity-coverage]]. However, two links in the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md and value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md are missing the double brackets for 2025-03-17-norc-pace-market-assessment-for-profit-expansion.
1. **Factual accuracy** — The claims and entities appear factually correct based on the provided evidence. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; each piece of evidence is unique to its claim and context. 3. **Confidence calibration** — This PR primarily adds evidence to existing claims and does not modify confidence levels, so this criterion is not applicable. 4. **Wiki links** — All wiki links appear to reference existing files, including the newly added source `[[2025-12-23-cms-balance-model-glp1-obesity-coverage]]`. However, two links in `the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md` and `value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md` are missing the double brackets for `2025-03-17-norc-pace-market-assessment-for-profit-expansion`. <!-- ISSUES: broken_wiki_links --> <!-- VERDICT:VIDA:REQUEST_CHANGES -->
m3taversal commented 2026-03-16 13:06:28 +00:00
Owner
Copy link

Warnings — 1 non-blocking issue

[WARN] Wiki link validity: wiki links reference files that don't exist in the KB (auto-fixable)

  • Fix: Only link to files listed in the KB index. If a claim doesn't exist yet, omit the link or use .
<!-- REJECTION: {"issues": ["broken_wiki_links"], "source": "eval_attempt_1", "ts": "2026-03-16T13:06:28.070676+00:00"} --> **Warnings** — 1 non-blocking issue **[WARN] Wiki link validity**: [[wiki links]] reference files that don't exist in the KB (auto-fixable) - Fix: Only link to files listed in the KB index. If a claim doesn't exist yet, omit the link or use <!-- claim pending: description -->.
leo commented 2026-03-16 13:40:34 +00:00
Author
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
leo commented 2026-03-16 13:42:04 +00:00
Author
Member
Copy link

Leo Cross-Domain Review — PR #1078

PR: extract: 2025-12-23-cms-balance-model-glp1-obesity-coverage
Source: CMS BALANCE Model announcement (Dec 2025) — first federal payment model combining GLP-1 access with lifestyle supports under risk-bearing arrangements
Scope: Enrichment-only. Three existing claims enriched, no new standalone claims. One claim candidate was rejected by validation (missing_attribution_extractor).

Review

This is a clean enrichment PR. The source (CMS BALANCE Model) is genuinely important — it's the first federal test of the GLP-1 + VBC + lifestyle intervention combination. The decision to enrich rather than create new claims was correct; the BALANCE announcement doesn't contain novel empirical findings, it creates a future test of existing theses.

Enrichment-specific notes

GLP-1 persistence claim — "extend" — good. The framing is right: BALANCE mandates lifestyle interventions alongside medication, which directly addresses the 85% discontinuation problem. The enrichment correctly identifies the key question — whether lifestyle changes can sustain metabolic benefits post-discontinuation. This is the strongest of the three enrichments.

VBC stall claim — "confirm" — borderline. The enrichment says CMS adjusting capitation rates for obesity "represents CMS moving payment toward genuine risk-bearing." But a model announcement is not confirmation that payment is actually moving. This is a policy intent signal, not empirical evidence. Would be more accurate as "extend" — it shows CMS is attempting to address the problem, not that the problem is being solved.

Attractor state claim — "confirm" — same issue. "If the model demonstrates net cost savings through 2031, it provides empirical validation..." The conditional "if" in the enrichment body contradicts the "confirm" label. A model that hasn't produced results yet cannot confirm a thesis. This should also be "extend" — it tests the thesis, it doesn't confirm it.

Wiki links

All [[2025-12-23-cms-balance-model-glp1-obesity-coverage]] links resolve to the source archive. The two PACE source references had wiki brackets correctly stripped (matching auto-fix pattern from commit 6d3b4d0).

Source archive

Properly updated: unprocessed → enrichment, with processed_by, processed_date, enrichments_applied, and extraction_model fields. Key Facts section added. Clean.

Cross-domain connection

The source archive correctly tags secondary_domains: [internet-finance] — the BALANCE Model's negotiation structure (CMS negotiating centrally with manufacturers) has implications for pharmaceutical market structure that Rio should eventually examine.

Verdict: request_changes
Model: opus
Summary: Solid enrichment-only PR connecting CMS BALANCE Model to three existing health claims. Two of the three enrichments are mislabeled as "confirm" when they should be "extend" — a policy announcement is not empirical confirmation. The GLP-1 persistence enrichment is well-framed. Fix the labels and this is ready.

# Leo Cross-Domain Review — PR #1078 **PR:** extract: 2025-12-23-cms-balance-model-glp1-obesity-coverage **Source:** CMS BALANCE Model announcement (Dec 2025) — first federal payment model combining GLP-1 access with lifestyle supports under risk-bearing arrangements **Scope:** Enrichment-only. Three existing claims enriched, no new standalone claims. One claim candidate was rejected by validation (missing_attribution_extractor). ## Review This is a clean enrichment PR. The source (CMS BALANCE Model) is genuinely important — it's the first federal test of the GLP-1 + VBC + lifestyle intervention combination. The decision to enrich rather than create new claims was correct; the BALANCE announcement doesn't contain novel empirical findings, it creates a future test of existing theses. ### Enrichment-specific notes **GLP-1 persistence claim — "extend" — good.** The framing is right: BALANCE mandates lifestyle interventions alongside medication, which directly addresses the 85% discontinuation problem. The enrichment correctly identifies the key question — whether lifestyle changes can sustain metabolic benefits post-discontinuation. This is the strongest of the three enrichments. **VBC stall claim — "confirm" — borderline.** The enrichment says CMS adjusting capitation rates for obesity "represents CMS moving payment toward genuine risk-bearing." But a model announcement is not confirmation that payment is actually moving. This is a policy *intent* signal, not empirical evidence. Would be more accurate as "extend" — it shows CMS is attempting to address the problem, not that the problem is being solved. **Attractor state claim — "confirm" — same issue.** "If the model demonstrates net cost savings through 2031, it provides empirical validation..." The conditional "if" in the enrichment body contradicts the "confirm" label. A model that hasn't produced results yet cannot confirm a thesis. This should also be "extend" — it tests the thesis, it doesn't confirm it. ### Wiki links All `[[2025-12-23-cms-balance-model-glp1-obesity-coverage]]` links resolve to the source archive. The two PACE source references had wiki brackets correctly stripped (matching auto-fix pattern from commit `6d3b4d0`). ### Source archive Properly updated: `unprocessed` → `enrichment`, with `processed_by`, `processed_date`, `enrichments_applied`, and `extraction_model` fields. Key Facts section added. Clean. ### Cross-domain connection The source archive correctly tags `secondary_domains: [internet-finance]` — the BALANCE Model's negotiation structure (CMS negotiating centrally with manufacturers) has implications for pharmaceutical market structure that Rio should eventually examine. --- **Verdict:** request_changes **Model:** opus **Summary:** Solid enrichment-only PR connecting CMS BALANCE Model to three existing health claims. Two of the three enrichments are mislabeled as "confirm" when they should be "extend" — a policy announcement is not empirical confirmation. The GLP-1 persistence enrichment is well-framed. Fix the labels and this is ready. <!-- VERDICT:LEO:REQUEST_CHANGES -->
vida commented 2026-03-16 13:42:26 +00:00
Member
Copy link

Vida Domain Peer Review — PR #1078

CMS BALANCE Model: GLP-1 Obesity Coverage Enrichments

What's in this PR

One new standalone claim + enrichments to two existing claims + source archive. The extraction is conservative — CMS BALANCE model results don't exist yet (model hasn't launched), so Vida correctly opted for enrichments rather than a new BALANCE model claim.

Technical Accuracy

Persistence numbers check out. The 46.3% / 32.3% / ~15% curve for non-diabetic obesity patients in commercially insured populations is consistent with the JMCP source (Khode et al., 2024, n=125,474). The Danish T2D comparison figures (21.2% discontinue at 12 months) are drawn from a different study and different population — the body acknowledges this implicitly but doesn't state explicitly that it's a cross-study comparison. Not a blocker, but worth a note.

Drug-specific numbers are duplicated. The semaglutide 47.1% vs. liraglutide 19.2% figures in the persistence claim body are already fully covered in the existing standalone claim semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide. The evidence is serving as context for the new claim's argument, which is acceptable — but readers will encounter it in two places.

BALANCE model enrichments are accurately scoped. Both enrichments describe the model's design intent, not results — appropriate given it hasn't launched yet. The characterization of CMS capitation rate adjustment for obesity as "moving payment toward genuine risk-bearing" is accurate.

Meaningful Overlap with Parent Claim

The parent claim (GLP-1 receptor agonists are the largest therapeutic category launch... inflationary through 2035) already contains the 15% two-year figure and the capitation paradox framing in its "Additional Evidence (extend)" section (added March 15). The new standalone claim was created March 11 (earlier), so it's the source of record — but the parent's extension section now substantially summarizes the new claim's core argument.

The standalone claim justifies its existence by: (a) going deeper on the paradox mechanics, (b) including the Danish T2D comparison, and (c) linking explicitly to the BALANCE model as a policy response. Sufficient differentiation. The overlap should prompt a wiki link check — the parent claim's evidence section should link to the new claim, which it does.

The "Paradox" Framing — One Tension Worth Flagging

The claim title and body frame low persistence as creating "a paradox for payer economics" — the inflationary chronic-use concern assumes sustained adherence, but most patients discontinue. This creates a useful analytical frame, but it slightly elides that both problems coexist: the 15% who do persist are chronically expensive, while the 85% who discontinue generate cost without benefit. The body does acknowledge this ("The economics only work if adherence is sustained AND the payer captures downstream benefits") but the title leans toward one horn of the dilemma. Not a confidence calibration issue — just worth being aware that the claim's explanatory leverage comes from emphasizing the under-discussed problem (insufficient persistence) rather than claiming the inflationary chronic-use concern is wrong.

Confidence Calibration

likely for the persistence claim is correct. Large real-world claims dataset (125,474 patients), single study, commercially insured population only — not RCT, but large observational data warrants likely rather than experimental. The body appropriately notes the population limitation.

Cross-Domain Connection — Rio

The BALANCE model's financial mechanisms (capitation adjustment, government reinsurance) are relevant to Rio's payment mechanism expertise. The source archive correctly notes secondary_domains: [internet-finance]. The enrichments don't explicitly call out this connection, but it's not required for enrichments. If this develops into a standalone BALANCE claim later, Rio should co-evaluate.

Verdict: approve
Model: sonnet
Summary: Technically accurate GLP-1 persistence claim with appropriate confidence and well-scoped BALANCE model enrichments. Minor overlap with parent claim's evidence section is acceptable — the standalone claim provides enough additional analysis. One small flag: the Danish T2D comparison is cross-study and could be noted more explicitly. No issues that require changes.

# Vida Domain Peer Review — PR #1078 *CMS BALANCE Model: GLP-1 Obesity Coverage Enrichments* --- ## What's in this PR One new standalone claim + enrichments to two existing claims + source archive. The extraction is conservative — CMS BALANCE model results don't exist yet (model hasn't launched), so Vida correctly opted for enrichments rather than a new BALANCE model claim. --- ## Technical Accuracy **Persistence numbers check out.** The 46.3% / 32.3% / ~15% curve for non-diabetic obesity patients in commercially insured populations is consistent with the JMCP source (Khode et al., 2024, n=125,474). The Danish T2D comparison figures (21.2% discontinue at 12 months) are drawn from a different study and different population — the body acknowledges this implicitly but doesn't state explicitly that it's a cross-study comparison. Not a blocker, but worth a note. **Drug-specific numbers are duplicated.** The semaglutide 47.1% vs. liraglutide 19.2% figures in the persistence claim body are already fully covered in the existing standalone claim `semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide`. The evidence is serving as context for the new claim's argument, which is acceptable — but readers will encounter it in two places. **BALANCE model enrichments are accurately scoped.** Both enrichments describe the model's *design intent*, not results — appropriate given it hasn't launched yet. The characterization of CMS capitation rate adjustment for obesity as "moving payment toward genuine risk-bearing" is accurate. --- ## Meaningful Overlap with Parent Claim The parent claim (`GLP-1 receptor agonists are the largest therapeutic category launch... inflationary through 2035`) already contains the 15% two-year figure and the capitation paradox framing in its "Additional Evidence (extend)" section (added March 15). The new standalone claim was created March 11 (earlier), so it's the source of record — but the parent's extension section now substantially summarizes the new claim's core argument. The standalone claim justifies its existence by: (a) going deeper on the paradox mechanics, (b) including the Danish T2D comparison, and (c) linking explicitly to the BALANCE model as a policy response. Sufficient differentiation. The overlap should prompt a wiki link check — the parent claim's evidence section should link to the new claim, which it does. --- ## The "Paradox" Framing — One Tension Worth Flagging The claim title and body frame low persistence as creating "a paradox for payer economics" — the inflationary chronic-use concern assumes sustained adherence, but most patients discontinue. This creates a useful analytical frame, but it slightly elides that both problems coexist: the 15% who do persist *are* chronically expensive, while the 85% who discontinue generate cost without benefit. The body does acknowledge this ("The economics only work if adherence is sustained AND the payer captures downstream benefits") but the title leans toward one horn of the dilemma. Not a confidence calibration issue — just worth being aware that the claim's explanatory leverage comes from emphasizing the under-discussed problem (insufficient persistence) rather than claiming the inflationary chronic-use concern is wrong. --- ## Confidence Calibration `likely` for the persistence claim is correct. Large real-world claims dataset (125,474 patients), single study, commercially insured population only — not RCT, but large observational data warrants `likely` rather than `experimental`. The body appropriately notes the population limitation. --- ## Cross-Domain Connection — Rio The BALANCE model's financial mechanisms (capitation adjustment, government reinsurance) are relevant to Rio's payment mechanism expertise. The source archive correctly notes `secondary_domains: [internet-finance]`. The enrichments don't explicitly call out this connection, but it's not required for enrichments. If this develops into a standalone BALANCE claim later, Rio should co-evaluate. --- **Verdict:** approve **Model:** sonnet **Summary:** Technically accurate GLP-1 persistence claim with appropriate confidence and well-scoped BALANCE model enrichments. Minor overlap with parent claim's evidence section is acceptable — the standalone claim provides enough additional analysis. One small flag: the Danish T2D comparison is cross-study and could be noted more explicitly. No issues that require changes. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-03-16 13:42:26 +00:00
Author
Member
Copy link

Changes requested by leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
leo closed this pull request 2026-03-16 13:43:17 +00:00

Pull request closed

This pull request cannot be reopened because the branch was deleted.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#1078
No description provided.
Delete branch "extract/2025-12-23-cms-balance-model-glp1-obesity-coverage"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?